Smith & Nephew SNATS Inc
$ 32.73
-0.70%
04 Dec - close price
- Market Cap 13,988,619,000 USD
- Current Price $ 32.73
- High / Low $ 33.12 / 32.68
- Stock P/E 29.43
- Book Value 6.33
- EPS 1.12
- Next Earning Report 2026-02-24
- Dividend Per Share $0.38
- Dividend Yield 2.31 %
- Next Dividend Date -
- ROA 0.06 %
- ROE 0.09 %
- 52 Week High 38.47
- 52 Week Low 23.11
About
Smith & Nephew plc (SNN) is a leading global medical technology company specializing in the development, manufacturing, and marketing of advanced medical devices across various sectors, including orthopedics, advanced wound management, and sports medicine. Headquartered in Watford, United Kingdom, Smith & Nephew leverages innovative technologies to enhance patient outcomes and drive efficiency in healthcare. With a strong commitment to research and development, the company continuously seeks to bring pioneering products to market, catering to healthcare professionals and patients worldwide.
Analyst Target Price
$37.03
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-05 | 2025-04-30 | 2025-03-10 | 2024-10-31 | 2024-08-01 | 2024-05-01 | 2024-02-27 | 2023-11-02 | 2023-08-03 | 2023-04-26 | 2023-02-21 |
| Reported EPS | 0 | 0.33 | 0 | 0.23 | 0 | 0.756 | 0 | 1.31 | 0 | 0.35 | 0 | 0.05 |
| Estimated EPS | 0 | 1.03 | 0 | 0.97 | 0 | 0.93 | 0 | 0.96 | 0 | 0.81 | 0 | 0.85 |
| Surprise | 0 | -0.7 | 0 | -0.74 | 0 | -0.174 | 0 | 0.35 | 0 | -0.46 | 0 | -0.8 |
| Surprise Percentage | None% | -67.9612% | None% | -76.2887% | None% | -18.7097% | None% | 36.4583% | None% | -56.7901% | None% | -94.1176% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-24 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 1.12 |
| Currency | USD |
Previous Dividend Records
| Nov 2025 | May 2025 | Nov 2024 | May 2024 | Nov 2023 | May 2023 | Oct 2022 | May 2022 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2025-11-07 | 2025-05-28 | 2024-11-08 | 2024-05-22 | 2023-11-01 | 2023-05-17 | 2022-10-26 | 2022-05-11 | None | None |
| Amount | $0.3 | $0.462 | $0.288 | $0.462 | $0.288 | $0.462 | $0.288 | $0.462 | $0.288 | $0.462 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SNN
2025-10-22 05:31:55
Smith+Nephew has launched its Coriograph pre-op planning and modeling services for total shoulder arthroplasty in the U.S. This software enables surgeons to create patient-specific plans for shoulder replacement procedures using advanced biomechanical simulation and works exclusively with the Cori surgical robot system. The launch completes Smith+Nephew's Coriograph portfolio, which also offers solutions for knee and hip arthroplasty, aiming to provide personalized orthopedic care.
2025-10-22 05:31:55
Smith & Nephew plc shareholders have seen a 14% CAGR over the last three years, with a 36% share price increase and a total shareholder return (TSR) of 48% including dividends. While EPS growth was 0.4% annually, significantly lower than the share price increase, the market's opinion of the company has improved, reflected in insider buying.
2025-10-22 05:31:55
RBC maintains an Outperform rating for Smith & Nephew, citing the company's strong positioning for upside potential as it transitions towards growth delivery. The medical products manufacturer is expected to benefit from strategic initiatives, with RBC raising its price target from GBP14 to GBP17.
2025-10-22 05:31:55
This article announces that Smith & Nephew plc has published its slide deck in conjunction with its Q2 2025 earnings call. The content is provided by SA Transcripts, which is responsible for developing and publishing thousands of quarterly earnings call transcripts.
2025-10-22 05:31:55
Smith & Nephew's shares jumped 9% after the company reported strong full-year sales and profits, driven by its 12-Point Plan restructuring efforts. The medical firm saw significant improvements in revenue and trading profit, along with substantial cost savings and successful product launches. While the dividend remained flat, the company anticipates further progress and margin expansion in 2025 despite challenges in the Chinese market.
2025-10-22 05:31:55
Smith & Nephew's chief financial officer, John Rogers, is relocating from the UK to the US, the company's largest market, to enhance executive leadership and oversight of operations. This move aligns with the fact that over half of the company's $5.8 billion revenues are generated in the US and most of its top executives are based there. Rogers' remuneration package will be adjusted to better reflect American executive compensation levels, following a new pay policy introduced after a shareholder revolt.
